Financial Services | Broking & Distribution | Asset Management | Private Wealth Management | Home Finance | Private Equity | Institutional Equities | Investment Banking | Commodities
Broking & Distribution > Markets > Company Information > News

Aurobindo Pharma Ltd

BSE Code : 524804   |   NSE Symbol : AUROPHARMA   |   ISIN : INE406A01037
Board of Aurobindo Pharma recommends dividend  06-Feb-2015 | 10:42
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 4 February 2015, inter alia, have recommended the dividend of Rs 2 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live News...
Aurobindo Pharma fixes record date for 2nd interim dividend   05-Feb-2015 | 10:04
Aurobindo Pharma has fixed 18 February 2015 as the Record Date for the purpose of payment of Second Interim Dividend 2014-15.The Second Interim Dividend will be paid on or before 25 February 2015.Powered by Capital Market - Live News...
Board of Aurobindo Pharma approves proposal to set up JV with Tergene Biotech   04-Feb-2015 | 21:22
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 04 February 2015, inter alia, has approved the proposal for setting up a Joint Venture (JV) with Tergene Biotech, a vaccine development company based in India. Tergene works on development of the Pneumococcal Conjugate Vaccine (PCV) through use of cutting edge vaccine technology compressing time and cos...
Aurobindo Pharma announces resignation of director   04-Feb-2015 | 21:14
Aurobindo Pharma announced that Dr.C.Channa Reddy an Independent Director of the Company vide letter dated 27 January 2015 has submitted his resignation due to personal reasons. The Board of Directors of the Company at the meeting held on 04 February 2015 has noted and taken on record the resignation of Dr.C.Channa Reddy as an Independent Director of the Company.Powered by Capital Mar...
Aurobindo Pharma to hold board meeting  20-Jan-2015 | 12:41
Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 4 February 2015, to consider the Un-Audited Financial Results of the Company for the quarter ended 31 December 2014 & the Board will also consider 2nd Interim Dividend, if any, for the financial year 2014-15.Powered by Capital Market - Live News...
Aurobindo Pharma allots equity shares   17-Jan-2015 | 11:01
Aurobindo Pharma announced that the Company has made allotment of 3,31,200 Equity Shares of Re.1/- each of the Company at a premium of Rs. 90.60 per equity share under ESOP-2006 of the Company on 17 January 2015. Consequent to the allotment, the paid up share capital of the Company has increased from 29,14,64,721 Equity Shares of Re.1/- each to 29,17,95,921 Equity Shares of Re.1/-each.Pow...
Aurobindo Pharma gets approval to launch Valsartan Tablets  06-Jan-2015 | 19:52
Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg (ANDA 202223). The product is ready for launch.Valsartan Tablets USP, 40mg, 80mg, 160mg and 320mg are the generic equivalent to the reference listed drug product (RLD) Diovan® Tablets, 40mg, 80mg, 160m...
Aurobindo Pharma to hold EGM  23-Dec-2014 | 09:24
Aurobindo Pharma announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 21 January 2015 .Powered by Capital Market - Live News...
Board of Aurobindo Pharma approves raising funds through QIP issue   11-Dec-2014 | 09:33
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 10 December 2014, have resolved subject to the approval of the members of the Company in terms of the provisions of the Companies Act, 2013 and of other applicable laws, regulations etc., issuance of Equity Shares through a Qualified Institutions Placement (“QIP) to Qualified Institutional Buyers (“QIB”) a...
Aurobindo Pharma announces completion of acquisition of Natrol   05-Dec-2014 | 16:48
Aurobindo Pharma announced the completion of acquisition of assets of nutritional supplement maker, Natrol Inc. and other affiliate entities (Natrol) through its wholly owned subsidiary Aurobindo Pharma USA Inc. (APUSA). APUSA emerged as the highest and best bidder to acquire assets of Natrol under the auction process by the United States Bankruptcy Court. APUSA acquired the manufacturing as...
  Company Information :   Company List A-Z  |   Snapshot  |   Volume Chart  |   Investor Returns  |   Score Board  |   Company Peer Comparison  |   Background  |   Board of Directors  |   Quarterly Results  |   Balance Sheet  |   Share Holding Pattern  |   MF Holdings  |   Profit & Loss  |   Key Ratios / Cash Flow  |   Company News  |   Bonus / Split / Rights  |   Dividend / Book Closure  |   Capital Structure  |   Insider Trading History  |   Top Companies By MCAP  |   Top Dividend Yield  
  Equity Market       Derivatives       Mutual Funds       Commodities       Currencies       News       IPO    
Login Open An Account Trade Now
7 day Free trial of our advice
High Speed Multi Asset trading - Orion Lite
Trading Insights
Trading Tool - Trade Guide Signal
Currency Daily Report
Financial Services Products & ServicesBusiness PartnerMarket InfoResearchQuick LinksBusinesses
Stocks   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Mutual Funds   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Commodities   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Disclaimer | Cookie Policy | Additional Disclaimer for U.S. Persons  | Feedback | Locate Us | Do Not Call Form
Motilal Oswal Securities Ltd. (MOSL) Member of NSE, BSE and MCX-SX
Regd Office: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; CIN no.: U65990MH1994PLC079418; Tel No.: 022 3980 4263
Correspondence Office Address: Motilal Oswal Securities Limited, Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West) Mumbai – 400064.; Tel No.: 022 3080 1000

Customer having any query / feedback / clarification may write to
In case of grievances for Securities Broking write to, for DP to, for Commodity Broking to

Registration Nos: NSE(Cash) INB231041238; NSE(F&O): INF231041238; NSE(CD): INE231041238; BSE(Cash): INB011041257; BSE(F&O) INF011041257; BSE(CD); MCX-SX (Cash) : INB261041231; MCX-SX (F&O): INF261041231; MCX-SX (CD): INE261041231; CDSL: IN-DP-CDSL-09-99; NSDL: IN-DP-NSDL-152-2000; AMFI:ARN 17397. PMS: INP000000670; PMS & Mutual Funds are offered through Motilal Oswal Asset Management Company Ltd(MOAMC) which is group company of MOSL. PMS (Regn No. INP000004409) is offered through Motilal Oswal Wealth Management Ltd. (MOWML) which is a group company of MOSL. Motilal Oswal Commodities Broker Pvt Ltd. (MOCBPL) member of MCX, NCDEX and NCDEX Spot. MCX Member ID 29500, NCDEX-NCDEX-CO-04-00114, NCDEX Spot Exchange Limited 10014. FMC Unique membership code: MCX: MCX/TCM/CORP/0725, NCDEX: NCDEX/TCM/CORP/0033, Commodity Services are offered through MOCBPL which a group company of Motilal Oswal Securities Ltd. Motilal Oswal Securities Ltd is a distributor of Mutual Fund & IPOs. Investment in Securities is subject to market risk.
Motilal Oswal Securities International Pvt Limited CRD-164319 SEC - 08-69093
Copyright © 2015 MOSL. All Rights Reserved. Market Data provided by C-MOTS Infotech (ISO 9001:2008 Certified)

Site best viewed in IE 7.0+, Mozila Firefox 3.0+ and Google Chrome at 1024 x 768 pixels resolution
Our research reports can be searched based on companies covered (COM), sectors covered (SEC) or report names (RPT). Type any three characters of your query to see a search list.